NASDAQ:HARPHarpoon Therapeutics Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Harpoon Therapeutics Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $12.75 +0.04 (+0.31 %) (As of 08/6/2020 02:57 PM ET) Add Compare Share Today's Range$12.47Now: $12.75▼$12.8850-Day Range$11.01MA: $15.46▼$18.3852-Week Range$10.27Now: $12.75▼$25.02Volume7,454 shsAverage Volume140,478 shsMarket Capitalization$318.75 millionP/E RatioN/ADividend YieldN/ABeta0.94 ProfileAnalyst RatingsAdvanced ChartCompetitorsEarningsInsider TradesInstitutional OwnershipHeadlinesSocial Media Harpoon Therapeutics, Inc., a clinical-stage immunotherapy company, engages in the development of a novel class of T cell engagers that harness the power of the body's immune system to treat patients suffering from cancer and other diseases in the United States. The company's lead TriTAC product candidate is HPN424 that is in Phase I clinical trial for the treatment of metastatic castration-resistant prostate cancer. It also develops HPN536 for the treatment of ovarian cancer and other MSLN-expressing tumors; HPN217 for the treatment of multiple myeloma; and HPN328 for the treatment of SCLC. The company has a collaboration agreement with AbbVie Biotechnology Ltd. Harpoon Therapeutics, Inc. was founded in 2015 and is headquartered in South San Francisco, California.Read More Beat the Market (BTM) Rank™ 4.5 Analyst's Opinion Consensus RatingHarpoon Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 7 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $30.43, Harpoon Therapeutics has a potential upside of 138.7% from its current price of $12.75.Amount of Analyst CoverageHarpoon Therapeutics has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 2.3 Community Rank Outperform VotesHarpoon Therapeutics has received 54 “outperform” votes. (Add your “outperform” vote.)Underperform VotesHarpoon Therapeutics has received 65 “underperform” votes. (Add your “underperform” vote.)Community SentimentHarpoon Therapeutics has received 54.62% “underperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Harpoon Therapeutics and other stocks. Vote “Outperform” if you believe HARP will outperform the S&P 500 over the long term. Vote “Underperform” if you believe HARP will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldHarpoon Therapeutics does not currently pay a dividend.Dividend GrowthHarpoon Therapeutics does not have a long track record of dividend growth. Previous Next 1.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Harpoon Therapeutics insiders have sold 2,332.53% more of their company's stock than they have bought. Specifically, they have bought $19,842.00 in company stock and sold $482,663.00 in company stock.Percentage Held by InsidersOnly 34.90% of the stock of Harpoon Therapeutics is held by insiders.Percentage Held by Institutions77.13% of the stock of Harpoon Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Harpoon Therapeutics are expected to remain at ($2.02) per share in the coming year.Price to Earnings Ratio vs. the MarketThe P/E ratio of Harpoon Therapeutics is -5.72, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Harpoon Therapeutics is -5.72, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioHarpoon Therapeutics has a P/B Ratio of 3.34. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 4.5Community Rank: 2.3Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.56 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:HARP Previous Symbol CUSIPN/A CIKN/A Webwww.harpoontx.com Phone650-443-7400Debt Debt-to-Equity Ratio0.16 Current Ratio5.40 Quick Ratio5.40Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$5.78 million Price / Sales55.15 Cash FlowN/A Price / Cash FlowN/A Book Value$3.82 per share Price / Book3.34Profitability EPS (Most Recent Fiscal Year)($2.55) Net Income$-55,570,000.00 Net Margins-681.41% Return on Equity-53.62% Return on Assets-34.20%Miscellaneous Employees45 Outstanding Shares25,000,000Market Cap$318.75 million Next Earnings Date11/4/2020 (Estimated) OptionableNot Optionable $12.75 +0.04 (+0.31 %) (As of 08/6/2020 02:57 PM ET) 30 days | 90 days | 365 days | Advanced Chart Receive HARP News and Ratings via Email Sign-up to receive the latest news and ratings for HARP and its competitors with MarketBeat's FREE daily newsletter. Harpoon Therapeutics (NASDAQ:HARP) Frequently Asked Questions How has Harpoon Therapeutics' stock been impacted by COVID-19 (Coronavirus)? Harpoon Therapeutics' stock was trading at $13.07 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, HARP stock has decreased by 2.4% and is now trading at $12.75. View which stocks have been most impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Harpoon Therapeutics? 7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Harpoon Therapeutics in the last year. There are currently 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Harpoon Therapeutics. When is Harpoon Therapeutics' next earnings date? Harpoon Therapeutics is scheduled to release its next quarterly earnings announcement on Wednesday, November 4th 2020. View our earnings forecast for Harpoon Therapeutics. How were Harpoon Therapeutics' earnings last quarter? Harpoon Therapeutics Inc (NASDAQ:HARP) posted its quarterly earnings data on Wednesday, August, 5th. The company reported ($0.51) EPS for the quarter, missing the Zacks' consensus estimate of ($0.47) by $0.04. Harpoon Therapeutics had a negative return on equity of 53.62% and a negative net margin of 681.41%. View Harpoon Therapeutics' earnings history. What price target have analysts set for HARP? 7 brokers have issued twelve-month price targets for Harpoon Therapeutics' stock. Their forecasts range from $24.00 to $38.00. On average, they anticipate Harpoon Therapeutics' stock price to reach $30.43 in the next year. This suggests a possible upside of 138.7% from the stock's current price. View analysts' price targets for Harpoon Therapeutics. Has Harpoon Therapeutics been receiving favorable news coverage? News headlines about HARP stock have been trending somewhat positive on Thursday, according to InfoTrie Sentiment Analysis. The research group identifies negative and positive press coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Harpoon Therapeutics earned a daily sentiment score of 1.4 on InfoTrie's scale. They also gave media stories about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the company's share price in the next several days. View the latest news about Harpoon Therapeutics. Are investors shorting Harpoon Therapeutics? Harpoon Therapeutics saw a increase in short interest in the month of July. As of July 31st, there was short interest totaling 522,900 shares, an increase of 17.2% from the July 15th total of 446,300 shares. Based on an average trading volume of 183,800 shares, the days-to-cover ratio is currently 2.8 days. Approximately 3.6% of the company's shares are sold short. View Harpoon Therapeutics' Current Options Chain. Who are some of Harpoon Therapeutics' key competitors? Some companies that are related to Harpoon Therapeutics include Coherus Biosciences (CHRS), Cortexyme (CRTX), Beam Therapeutics (BEAM), Alector (ALEC), Compugen (CGEN), Adaptimmune Therapeutics (ADAP), I-Mab (BDTX), Nantkwest (NK), Vaxart (VXRT), Translate Bio (TBIO), BAVARIAN NORDIC/S (BVNRY), Replimune Group (REPL), Poseida Therapeutics (PSTX), Atara Biotherapeutics (ATRA) and Cellectis (CLLS). View all competitors. What other stocks do shareholders of Harpoon Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Harpoon Therapeutics investors own include Alector (ALEC), Editas Medicine (EDIT), Gossamer Bio (GOSS), Precision BioSciences (DTIL), Tcr2 Therapeutics (TCRR), Kaleido Biosciences (KLDO), LogicBio Therapeutics (LOGC), Homology Medicines (FIXX), NVIDIA (NVDA) and Stoke Therapeutics (STOK). Who are Harpoon Therapeutics' key executives? Harpoon Therapeutics' management team includes the following people: Dr. Luke B. Evnin, Chairman (Age 56)Dr. Gerald McMahon, Pres, CEO & Director (Age 64)Dr. Holger Wesche Ph.D., Chief Scientific Officer (Age 51)Dr. Natalie R. Sacks, Chief Medical Offer (Age 54)Ms. Georgia L. Erbez, Chief Financial Officer (Age 52) When did Harpoon Therapeutics IPO? (HARP) raised $76 million in an initial public offering on Friday, February 8th 2019. The company issued 5,400,000 shares at $13.00-$15.00 per share. Citigroup and Leerink Partners acted as the underwriters for the IPO and Canaccord Genuity and Wedbush PacGrow were co-managers. What is Harpoon Therapeutics' stock symbol? Harpoon Therapeutics trades on the NASDAQ under the ticker symbol "HARP." Who are Harpoon Therapeutics' major shareholders? Harpoon Therapeutics' stock is owned by many different institutional and retail investors. Top institutional shareholders include Bessemer Group Inc. (0.13%), Russell Investments Group Ltd. (0.09%), Virtus ETF Advisers LLC (0.08%), Strs Ohio (0.05%) and UBS Group AG (0.03%). Company insiders that own Harpoon Therapeutics stock include Bioscience Plc Arix, Georgia Erbez, Gerald Phd Mcmahon, Holger Wesche, Luke Evnin, Mark Chin, Natalie Sacks and Patrick Baeuerle. View institutional ownership trends for Harpoon Therapeutics. Which major investors are selling Harpoon Therapeutics stock? HARP stock was sold by a variety of institutional investors in the last quarter, including UBS Group AG. Company insiders that have sold Harpoon Therapeutics company stock in the last year include Bioscience Plc Arix, Holger Wesche, Mark Chin, Natalie Sacks, and Patrick Baeuerle. View insider buying and selling activity for Harpoon Therapeutics. Which major investors are buying Harpoon Therapeutics stock? HARP stock was purchased by a variety of institutional investors in the last quarter, including Bessemer Group Inc., Virtus ETF Advisers LLC, Strs Ohio, and Russell Investments Group Ltd.. Company insiders that have bought Harpoon Therapeutics stock in the last two years include Bioscience Plc Arix, Georgia Erbez, Gerald Phd Mcmahon, and Luke Evnin. View insider buying and selling activity for Harpoon Therapeutics. How do I buy shares of Harpoon Therapeutics? Shares of HARP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Harpoon Therapeutics' stock price today? One share of HARP stock can currently be purchased for approximately $12.75. How big of a company is Harpoon Therapeutics? Harpoon Therapeutics has a market capitalization of $318.75 million and generates $5.78 million in revenue each year. The company earns $-55,570,000.00 in net income (profit) each year or ($2.55) on an earnings per share basis. Harpoon Therapeutics employs 45 workers across the globe. What is Harpoon Therapeutics' official website? The official website for Harpoon Therapeutics is www.harpoontx.com. How can I contact Harpoon Therapeutics? Harpoon Therapeutics' mailing address is 131 OYSTER POINT BLVD SUITE 300, SOUTH SAN FRANCISCO CA, 94080. The company can be reached via phone at 650-443-7400 or via email at [email protected] This page was last updated on 8/6/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
